A Phase 3 Study of an Experimental Gene Therapy for Oculopharyngeal Muscular Dystrophy Will Take Place, Axovant Says
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

A Phase 3 Study of an Experimental Gene Therapy for Oculopharyngeal Muscular Dystrophy Will Take Place, Axovant Says

An experimental gene therapy program (called AXO-AAV-OPMD) being developed for the treatment of oculopharyngeal muscular dystrophy has been licensed with exclusive global rights to Axovant Sciences from Benitec Biopharma. There…

Continue Reading
Close Menu